Effects of Pomegranate Seed Oil on Heart Health in Postmenopausal Women
Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers in Postmenopausal Women.
This study is testing if pomegranate seed oil can improve heart health markers in healthy postmenopausal women.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | N/A to 65 Years |
| Sex | Female |
| Sponsor | University of Reading Academic / other |
| Locations | 1 site (Reading) |
| Trial ID | NCT06042673 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of pomegranate seed oil on cardiovascular disease risk markers in postmenopausal women. It employs a cross-over, single-blind, randomized design where participants will consume either a placebo or pomegranate seed oil mixed with vegetable oil on two separate occasions. The study aims to assess how these dietary fats influence postprandial vascular function and lipid profiles. A total of 15 healthy postmenopausal women will be recruited for this acute postprandial study.
Who should consider this trial
Good fit: Ideal candidates are postmenopausal women aged 65 and under with specific lipid and glucose levels.
Not a fit: Patients with a history of cardiovascular events, diabetes, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into dietary interventions that improve heart health in postmenopausal women.
How similar studies have performed: While there is limited research specifically on pomegranate seed oil, studies on dietary fats and cardiovascular health have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Postmenopausal women who have been postmenopausal for at least 12 months. * Aged 65 and under years * Serum TAG \< 2.3 mmol/l * Body mass index (BMI) between 18-35 kg/m2 * Fasting total cholesterol \< 7.5 mmol/l * Fasting glucose concentration \<7 mmol/L Exclusion Criteria: * Smokers * Medical history of myocardial infarction or stroke in the past 12 months * Diabetes (defined as fasting glucose \> 7.0 mmol/l) or other endocrine disorders * Kidney, liver, pancreas or gastrointestinal disorder * Hypertension (blood pressure \> 140/90 mmHg), cancer, medication for hyperlipidaemia (e.g. statins), hypertension or, inflammation * Anaemia (\<115 g/L haemoglobin) * Taking any dietary supplements known to influence lipids/gut microbiota (e.g. plant stanols, fish oil, phytochemicals, natural laxatives, probiotics and prebiotics) * Drinking in excess of 14 units of alcohol per week * Planning on a weight-reducing regime * Parallel participation in another dietary intervention study * Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study
Where this trial is running
Reading
- Department of Food and Nutritional Sciences, University of Reading — Reading, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Jeremy Spencer, BSc, PhD
- Email: j.p.e.spencer@reading.ac.uk
- Phone: +44(0)1183788724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.